# US 2017/0281624 A1 · Combination therapies of alk inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281624 A1
- Document ID: US20170281624A1
- Status: Published application
- Kind: A1
- Application number: 15/509,649
- Filed: 2015-09-11
- Published: 2017-10-05
- Earliest claimed: 2014-09-13
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Malte Peters; David LEBWOHL; Jeffrey SCOTT; Nanxin LI; Yvonne LAU
- Web page: https://patentgrep.com/patent/US20170281624A1

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/3023: {Lung}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/542: {oral/gastrointestinal}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A method of treating a cancer in a subject is disclosed, comprising administering to the subject an immunomodulator and a second therapeutic agent, wherein: (i) the immunomodulator is chosen from one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule, and (ii) the second therapeutic agent is LDK378, thereby treating the cancer.

## Claims

### Claim 1

A method of treating a cancer in a subject, comprising administering to the subject an immunomodulator and a second therapeutic agent, wherein:
(i) the immunomodulator is chosen from one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule, and
(ii) the second therapeutic agent is LDK378,
thereby treating the cancer.

### Claim 2

A method of reducing growth, survival, or viability, or all, of a a cancer cell, comprising contacting the cell with an immunomodulator and a second therapeutic agent, wherein:
(i) the immunomodulator is chosen from one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule, and
(ii) the second therapeutic agent is LDK378,
thereby reducing the growth, survival, or viability of the cancer cell.

### Claim 3 (depends on 1)

The method of claim 1, wherein the agonist of the costimulatory molecule is chosen from an agonist of one or more of OX40, CD2, CD27, CDS, ICAM-1, LFA-1 (CD11a/CD18), 1COS (CD278), 4-1BB (CD137), GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3 or CD83 ligand.

### Claim 4 (depends on 1)

The method of claim 1, wherein the inhibitor of the immune checkpoint molecule is chosen from one or more of PD-1, PD-L1, PD-L2, CTLA4, TIM3, LAGS, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGFR beta.

### Claim 5 (depends on 1)

The method of claim 1, wherein the inhibitor of the immune checkpoint molecule is chosen from an inhibitor of PD-1, PD-L1, LAG-3, TIM-3 or CTLA4, or any combination thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the combination of the immunomodulator and the LDK378 can be administered together in a single composition or administered separately in two or more different compositions.

### Claim 7 (depends on 1)

The method of claim 1, wherein the combination of the immunomodulator and the LDK378 is administered or contacted concurrently with, prior to, or subsequent to, the second agent.

### Claim 8 (depends on 1)

The method of claim 1, wherein the inhibitor of the immune checkpoint molecule is a soluble ligand or an antibody or antigen-binding fragment thereof, that binds to the immune checkpoint molecule.

### Claim 9 (depends on 1)

The method of claim 1, wherein the antibody or antigen-binding fragment thereof is from an IgG1 or IgG4 (e.g., human IgG1 or IgG4).

### Claim 10 (depends on 1)

The method of any of claimc 1 ° claim 1, wherein the antibody molecule is a bispecific or multispecific antibody molecule that has a first binding specificity to PD-1 or PD-L1 and a second binding specifity to TIM-3, LAG-3, or PD-L2.

### Claim 11 (depends on 1)

The method of claim 1, wherein the immunomodulator is an anti-PD-1 antibody chosen from Nivolumab, Pembrolizumab or Pidilizumab.

### Claim 12 (depends on 1)

The method of claim 1, wherein the immunomodulator is an anti-PD-L1 antibody chosen from YW243.55.S70, MPDL3280A, MEDI-4736, MSB-0010718C, or MDX-1105.

### Claim 13 (depends on 1)

The method of claim 1, wherein the immunomodulator is an anti-LAG-3 antibody molecule.

### Claim 14 (depends on 13)

The method of claim 13, wherein the anti-LAG-3 antibody molecule is BMS-986016.

### Claim 15 (depends on 1)

The method of claim 1, wherein the immunomodulator is an anti-PD-1 antibody chosen from Nivolumab or Pembrolizumab.

### Claim 16 (depends on 1)

The method of any of claims 1 11claim 1, wherein the immunomodulator is Nivolumab.

### Claim 17 (depends on 1)

The method of claim 1, wherein the immunomodulator is the anti-PD-L1 antibody, MSB0010718C.

### Claim 18 (depends on 1)

The method of claim 1, wherein the cancer is a solid tumor, a soft tissue tumor, and a metastatic lesion of any of the aforesaid cancers.

### Claim 19 (depends on 1)

The method of claim 1, wherein the cancer is a solid tumor from the lung; breast; ovarian; lymphoid; gastrointestinal such as colon; anal; genitals and genitourinary tract such as renal, urothelial, bladder cells, prostate; pharynx; CNS such as brain, neural or glial cells; head and neck; skin such as melanoma); pancreas; renal-cell carcinoma; liver, non-small cell lung cancer, small intestine or the esophagus.

### Claim 20 (depends on 1)

The method of claim 1, wherein the cancer is a hematological cancer chosen from a Hogdkin's lymphoma, a non-Hodgkin's lymphoma, a lymphocytic leukemia, or a myeloid leukemia.

### Claim 21 (depends on 1)

The method of claim 1, wherein the cancer is chosen from a cancer disclosed in Table 1.

### Claim 22 (depends on 1)

The method of claim 1, wherein the subject is a human (e.g., a patient having, or at risk of having, a cancer described herein.

### Claim 23 (depends on 1)

The method of claim 1, wherein the immunomodulator is an anti-PD-1 antibody molecule administered by injection (e.g., subcutaneously or intravenously) at a dose of about 1 to 30 mg/kg, about 5 to 25 mg/kg, about 10 to 20 mg/kg, about 1 to 5 mg/kg, or about 3 mg/kg, once a week to once every 2, 3, or 4 weeks.

### Claim 24 (depends on 23)

The method of claim 23, wherein the anti-PD-1 antibody molecule is administered at a dose from about 10 to 20 mg/kg every other week.

### Claim 25 (depends on 23)

The method of claim 23, wherein the anti-PD-1 antibody moleculeNivolumab is administered intravenously at a dose from about 1 mg/kg to 3 mg/kg, about 1 mg/kg, 2 mg/kg or 3 mg/kg, every two weeks.

### Claim 26 (depends on 23)

The method of claim 23, wherein the anti-PD-1 antibody molecule Nivolumab, is administered intravenously at a dose of about 2 mg/kg at 3-week intervals.

### Claim 27 (depends on 23)

The method of claim 23, wherein the anti-PD-1 antibody molecule Nivolumab is administered intravenously at a dose of about 3 mg/kg at 2-week intervals.

### Claim 28 (depends on 1)

The method of claim 1, wherein the immunomodulator is Nivolumab, Pembrolizumab, or MSB0010718C

### Claim 29 (depends on 1)

The method of claim 1, wherein the immunomodulator is Nivolumab, Pembrolizumab, or MSB0010718C used in combination with LDK378 to treat a cancer described in Table 1 such as a solid tumor, or a lung cancer, or non-small cell lung cancer (NSCLC).

### Claim 30 (depends on 1)

The method of claim 1, wherein the immunomodulator is Nivolumab, Pembrolizumab, or MSB0010718C used in combination with LDK378 to treat a cancer, wherein the cancer is lymphoma, such as an anaplastic large-cell lymphoma or non-Hodgkin's lymphoma.

### Claim 31 (depends on 1)

The method of claim 1, wherein the immunomodulator is Nivolumab, Pembrolizumab, or MSB0010718C used in combination with LDK378 to treat a cancer, wherein the cancer is an inflammatory myofibroblastic tumor.

### Claim 32 (depends on 1)

The method of claim 1, wherein the immunomodulator is Nivolumab, Pembrolizumab, or MSB0010718C used in combination with LDK378 to treat a cancer, wherein the cancer is neuroblastoma.

### Claim 33 (depends on 36)

The method of claim 36, wherein the cancer is an NSCLC such asa Stage IIIB or IV NSCLC, or a relapsed locally advanced or metastatic NSCLC.

### Claim 34 (depends on 29)

The method of claim 29, wherein the cancer has, or is identified as having an ALK rearrangement or translocation.

### Claim 35 (depends on 34)

The method of claim 34, wherein the cancer has, an ALK fusion.

### Claim 36 (depends on 34)

The method of claim 34, wherein the cancer has an EML4-ALK fusion.

### Claim 37 (depends on 33)

The method according to claim 33, wherein the cancer has progressed on, or is tolerant to, crizotinib.

### Claim 38 (depends on 33)

The method according to claim 33, wherein LDK378 is administered at an oral dose of about 100 to 1000 mg.

### Claim 39 (depends on 33)

The method according to claim 33, wherein LDK378 is administered at an oral dose from about 150 mg to 750 mg daily, either with food or in a fasting condition.

### Claim 40 (depends on 33)

The method according to claim 33, wherein LDK378 is administered at an oral dose of about 750 mg daily, in a fasting condition.

### Claim 41 (depends on 33)

The method according to claim 33, wherein LDK378 is administered at an daily oral dose of about 750 mg or lower, about 600 mg or lower,or about 450 mg or lower, via capsule or tablet.

### Claim 42

A composition comprising an immunomodulator such as one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule and LDK378.

### Claim 43

A pharmaceutical combination comprising (i) LDK378, or a pharmaceutically acceptable salt thereof, and (ii) nivolumab, or a pharmaceutically acceptable salt thereof.

### Claim 44 (depends on 43)

The pharmaceutical combination according to claim 43 comprising components (i) and (ii) separately or together.

### Claim 45 (depends on 43)

The pharmaceutical combination according to claim 43 for use as a medicine, wherein LDK378 and the Nivolumab are administered independently at the same time or separately within time intervals.

### Claim 46 (depends on 45)

The pharmaceutical combination according to claim 45, wherein time intervals allow that the combination partners are jointly active.

### Claim 47 (depends on 43)

The pharmaceutical combination according to claim 43 comprising a quantity which is jointly therapeutically effective for the treatment of an ALK mediated disease.

### Claim 48 (depends on 47)

The pharmaceutical combination according to claim 47, wherein the ALK mediated disease is cancer.

### Claim 49 (depends on 47)

The pharmaceutical combination according to claim 47, wherein the ALK mediated disease is NSCLC or lymphoma,

### Claim 50 (depends on 47)

The pharmaceutical combination according to claim 47, wherein the ALK mediated disease is NSCLC.

### Claim 51 (depends on 43)

The pharmaceutical combination according to claim 43, wherein ceritinib dose is 450 mg and nivolumab dose is 3 mg/kg.

### Claim 52 (depends on 43)

The pharmaceutical combination according to claim 43, wherein ceritinib dose is 600 mg and nivolumab dose is 3 mg/kg.

### Claim 53 (depends on 43)

The pharmaceutical combination according to claim 43, wherein ceritinib is administered with a low fat meal.
